- Revusiran, an investigational RNAi therapeutic targeting TTR for the treatment of ATTR amyloidosis in patients with familial amyloidotic cardiomyopathy (FAC). Alnylam plans to:
- Continue enrollment in the ENDEAVOUR Phase 3 study.
- Based on ongoing enrollment, the Company is guiding today that it expects to report data from the ENDEAVOUR trial in 2018.
- Continue enrollment in the ENDEAVOUR Phase 3 study.
Catalyst
Slingshot members are tracking this event:
Phase 3 data of Revusiran ENDEAVOUR trial for ATTR in patients with familial amyloidotic cardiomyopathy (FAC) due 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALNY | Community voting in process | |||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 05, 2016
Occurred Source:
http://investors.alnylam.com/releasedetail.cfm?ReleaseID=992320
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Data, Revusiran, Endeavour, Attr, Amyloidotic Cardiomyopathy, Fac
